Pricing Log in Create free account

INmune Bio, Inc. (INMB) vs Promis Neurosciences (PMN)

INmune Bio, Inc. and Promis Neurosciences are both Biotechnology companies. INmune Bio, Inc. and Promis Neurosciences are of similar size ($32.7M and $32.6M). Promis Neurosciences grew revenue faster over the last twelve months: 450.0% against −51.6%. Across the 13 metrics below, INmune Bio, Inc. leads on 7 and Promis Neurosciences on 6.

Valuation

Metric INMB PMN Biotechnology median
P/E n/m n/m 10.60
P/S 221.67 16,913.44 9.40
P/B 1.47 0.75 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 0.28 0.66
EV/Sales 121.37 (5,572.97) 9.02
Earnings yield (59.82%) (324.53%) (32.88%)
Free cash flow yield (54.91%) (113.16%) (23.13%)

Profitability

Metric INMB PMN Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (74.82%) (172.30%) (51.96%)
Return on assets (57.08%) (127.57%) (46.06%)
Return on invested capital (646.94%) 0.00% 0.00%

Growth

Metric INMB PMN Biotechnology median
Revenue growth (TTM) (51.61%) 450.00% 6.76%
EPS growth (last fiscal year) 11.85% (922.18%) 29.88%
Revenue growth, 5-year CAGR 35.37% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INMB PMN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.04 7.85 4.97
Net debt to EBITDA 0.52 0.15 1.01

Dividend

Metric INMB PMN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INMB PMN Biotechnology median
Market cap 32.61m 32.74m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack